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Abstract
 
Increasing evidence has revealed that mast cell–derived tumor necrosis factor 
 
  
 
(TNF-
 
 
 
) plays
a critical role in a number of inflammatory responses by recruiting inflammatory leukocytes. In
this paper, we investigated the regulatory role of interleukin 4 (IL-4) in TNF-
 
 
 
 production in
 
mast cells. IL-4 inhibited immunoglobulin E–induced TNF-
 
 
 
 production and neutrophil
recruitment in the peritoneal cavity in wild-type mice but not in signal transducers and activators
of transcription 6 (Stat6)–deficient mice. IL-4 also inhibited TNF-
 
 
 
 production in cultured
mast cells by a Stat6-dependent mechanism. IL-4–Stat6 signaling induced TNF-
 
 
 
 mRNA
destabilization in an AU-rich element (ARE)–dependent manner, but did not affect TNF-
 
 
 
promoter activity. Furthermore, IL-4 induced the expression of tristetraprolin (TTP), an
RNA-binding protein that promotes decay of ARE-containing mRNA, in mast cells by a
Stat6-dependent mechanism, and the depletion of TTP expression by RNA interference
prevented IL-4–induced down-regulation of TNF-
 
 
 
 production in mast cells. These results
suggest that IL-4–Stat6 signaling induces TTP expression and, thus, destabilizes TNF-
 
 
 
mRNA in an ARE-dependent manner.
Key words: mast cell–derived TNF-
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Introduction
 
Mast cells are one of the major producers of TNF-
 
 
 
 (1–3),
and mast cell–derived TNF-
 
 
 
 has been shown to play a
critical role in several inflammatory responses (4–10). Mast
cells produce TNF-
 
 
 
 upon stimulation via the high-affinity
receptors for IgE (2, 3), and the mast cell–derived TNF-
 
 
 
is believed to be involved in the induction of IgE-dependent
allergic inflammation (4, 11).
Recent works have revealed that mast cell–derived
TNF-
 
 
 
 also plays important roles in other inflammatory
processes of both innate and acquired immune responses.
It has been shown that mast cell–derived TNF-
 
 
 
 is in-
volved in the protection against gram-negative bacteria in
experimental peritonitis (5, 6), immune complex–mediated
peritonitis (7), T cell–mediated delayed-type hypersensi-
tivity reaction (8), and autoantibody-induced arthritis (9,
10). Although TNF-
 
 
 
 is beneficial in some situations
such as bacterial infection (5, 6), an excess of TNF-
 
 
 
seems harmful in other situations (4, 7–10). Therefore,
the production of TNF-
 
 
 
 should be tightly controlled in
mast cells.
IL-4 is a multifunctional cytokine that plays a central role
in causing allergic Th2-type immune responses (12, 13).
Binding of IL-4 to IL-4R results in the activation of signal
transducers and activators of transcription 6 (Stat6) and
induces the expression of IL-4–inducible genes, including
class II major histocompatibility molecules, low-affinity IgE
receptor (CD23), and IL-4R
 
 
 
 chain (12, 13). IL-4–Stat6
signaling plays a central role in the commitment of CD4
 
 
 
T cells to the Th2 phenotype and IgE isotype switching in
B cells (12, 13). On the other hand, it has been shown that
IL-4–Stat6 signaling enhances IL-10–induced apoptosis of
IL-3–dependent mast cells (14) and decreases the expression
of IgE receptors on mast cells (15). However, the regulatory
role of IL-4 in TNF-
 
 
 
 production in mast cells is still
largely unknown.
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In this paper, we investigated the molecular basis for IL-
4–induced regulation of TNF-
 
 
 
 production in mast cells.
We found that IL-4–Stat6 signaling down-regulated TNF-
 
 
 
production in mast cells by destabilizing mRNA in an
AU-rich element (ARE)–dependent manner. We also
found that IL-4 induced the expression of tristetraprolin
(TTP), an RNA-binding zinc-finger protein that promotes
decay of ARE-containing mRNAs (16–18), by a Stat6-
dependent mechanism and that the depletion of TTP by
RNA interference (RNAi) prevented IL-4–induced down-
regulation of TNF-
 
 
 
 production. Our results indicate that
IL-4–Stat6 signaling induces TTP expression and subse-
quent ARE-dependent mRNA destabilization, resulting in
the down-regulation of TNF-
 
 
 
 production in mast cells.
 
Materials and Methods
 
Mice.
 
Stat6-deficient (Stat6
 
 
 
/
 
 
 
) mice (19) were backcrossed
for more than eight generations onto C57BL/6 mice (Japan SLC)
or BALB/c mice (Charles River Laboratories), and the littermate
WT mice were used as controls. C57BL/6 background mice
were used except for the experiments of IgE-dependent late-
phase reactions. Stat6
 
   
 
 mice were obtained from S. Akira and
K. Takeda (both from Research Institute for Microbial Diseases,
Osaka University, Osaka, Japan). Mice were housed in microiso-
lator cages under pathogen-free conditions. All experiments were
performed according to the guidelines of Chiba University.
 
Constructs.
 
COOH-terminal–truncated Stat6 mutant at amino
acid 673 (673 Stat6) was described previously (20). A constitu-
tively active form of Stat6 (Stat6VT; reference 21), which has
two alanine substitutions at amino acids 547 and 548, was gener-
ated using a PCR-based site-directed mutagenesis kit according
to the manufacturer’s instruction (Stratagene). All mutations were
confirmed by DNA sequencing.
 
Cell Culture.
 
BMMCs were prepared and maintained as de-
scribed previously (20). More than 98% of cells obtained after 4
wk of culture were morphologically mast cells and positive for
c-kit expression. CFTL-15 cells (obtained from M.A. Brown, Em-
ory University School of Medicine, Atlanta, GA), a murine mast
cell line, were cultured in RPMI 1640 medium containing 10%
heat-inactivated FCS, 50 mM 
 
 
 
-mercaptoethanol, 2 mM 
 
l
 
-glu-
tamine, antibiotics, and 10% (vol/vol) murine IL-3 transfectant
X63 cell–conditioned medium as a source of IL-3 (complete
RPMI 1640 medium). X63–IL-3 cells were obtained from H.
Karasuyama (Tokyo Metropolitan Organization of Medical Sci-
ence, Tokyo, Japan).
 
Stimulation of BMMCs and CFTL-15 Cells.
 
For stimulation
of BMMCs via Fc
 
 
 
 receptors, BMMCs were incubated with 1
 
 
 
g/ml mouse anti-DNP IgE (YAMASA) at 37
 
 
 
C for 2 h, washed
twice with RPMI 1640 medium, and incubated with 50 ng/ml
DNP-HSA (human serum albumin; Sigma-Aldrich) at 37
 
 
 
C for 6
or 24 h. In some experiments, BMMCs or CFTL-15 cells were
stimulated with 500 ng/ml A23187 (Sigma-Aldrich) at 37
 
 
 
C for
24 h. Where indicated, 10 ng/ml murine recombinant IL-4
(R&D Systems) was added to the culture.
 
IgE-dependent Late-phase Reactions.
 
IgE-dependent late-phase
reactions in the mouse peritoneal cavity were induced as de-
scribed previously (22). In brief, mouse anti-DNP IgE (100 
 
 
 
g
per mouse) or PBS (as a control) was injected intravenously to
BALB/c mice or Stat6
 
 
 
/
 
 
 
 mice. Murine IL-4 (1 
 
 
 
g per mouse)
or PBS (as a control) was injected intraperitoneally to the mice
 
24 h after anti-DNP IgE or PBS injection. 1 h later, DNP-HSA
(6 
 
 
 
g in 0.2 ml of saline) or saline (as a control) was injected in-
traperitoneally to the mice. Peritoneal lavage was performed with
1 ml of ice-cold PBS 8 h after DNP-HSA injection. The number
of total cells in the lavage fluid was counted with a hemocytome-
ter, and differential cell counts were determined on the cytospin
cell preparations stained with Wright–Giemsa solution. The
amount of TNF-
 
 
 
 in the peritoneal lavage fluid was determined
by ELISA as described in the next paragraph.
 
Measurement of TNF-
 
 
 
 by ELISA.
 
The amount of TNF-
 
 
 
 in
the culture supernatant or in the peritoneal lavage fluid was mea-
sured using a murine TNF-
 
 
 
 ELISA kit (BD Biosciences). The
assay was performed in duplicate according to the manufacturer’s
instructions. The detection limit was 15 pg/ml.
 
Intracellular Staining for TNF-
 
 
 
.
 
BMMCs were stimulated
with IgE engagement or A23187 in the presence or absence of 10
ng/ml IL-4 at 37
 
 
 
C for 6 h, with 2 
 
 
 
M monensin (Sigma-
Aldrich) added for the final 4 h to prevent cytokine release. Cells
were harvested, washed with PBS, and stained with anti–c-kit PE
(2B8; BD Biosciences) for 30 min at 4
 
 
 
C. Cells were washed
with PBS, fixed with IC Fix (Biosource International), permeabi-
lized with IC Perm (Biosource International), and stained with
anti–TNF-
 
 
 
 allophycocyanin (MP6-XT22; BD Biosciences) for
30 min at 4
 
 
 
C. After washing, cells were analyzed on FACScali-
bur™ using CELLQuest™ software.
 
Retrovirus-mediated Gene Expression.
 
To overcome the limited
efficiency of transfection on BMMCs, we used a bicistronic ret-
rovirus system, in which infected cells were identified by coex-
pressed green fluorescent protein (GFP; pMX-IRES-GFP vector;
reference 23) or coexpressed Thy1.1 (MSCV-IRES-Thy1.1 vec-
tor, obtained from P. Marrack, National Jewish Medical and Re-
search Center, Denver, CO; reference 24). pMX-IRES-GFP
vector was obtained from T. Kitamura (Institute of Medical Sci-
ence, University of Tokyo, Tokyo, Japan). Retroviral vectors
pMX-WT Stat6-IRES-GFP, pMX-673 Stat6-IRES-GFP, and
pMX-IRES-GFP (as a control) were described previously (20).
Retrovirus-mediated gene expression for BMMCs was per-
formed as described previously (20). Efficiency of infection to
BMMCs was 8–15% in all viruses as assessed by FACS
 
®
 
.
CFTL-15 cells were infected with retroviruses of MSCV-
Stat6VT-IRES-Thy1.1 or MSCV-IRES-Thy1.1 (as a control),
and retrovirus-infected cells (Thy1.1
 
 
 
 cells) were purified by
magnetic cell sorting as described previously (20). The purity of
Thy1.1
 
 
 
 cells was routinely 
 
 
 
95%.
 
TNF-
 
 
 
 Promoter Assay.
 
Reporter construct of TNF-
 
 
 
 pro-
moter (pGL3TNF; reference 25), in which full-length murine
TNF-
 
 
 
 promoter (26) drives the luciferase gene, was a gift from
E.W. Gelfand (National Jewish Medical and Research Center,
Denver, CO). CFTL-15 cells were transfected with pGL3TNF in
the presence of pRL-TK (Promega) in 800 
 
 
 
l of serum-free
RPMI 1640 medium at 960 
 
 
 
F/300 V. Where indicated, WT
Stat6 expression vector (pcDNA3 Stat6), Stat6VT expression
vector (pcDNA3 Stat6VT), or pcDNA3 (as a control) was
cotransfected. After cells were cultured in complete RPMI 1640
medium at 37
 
 
 
C for 12 h, aliquoted cells were left treated or un-
treated with 10 ng/ml IL-4 for another 12 h. The luciferase activ-
ity was measured by the dual luciferase assay system (Promega)
according to the manufacturer’s instructions. Firefly luciferase ac-
tivity of pGL3TNF was normalized by Renilla luciferase activity
of pRL-TK. All values were obtained from experiments per-
formed in triplicate and repeated at least three times.
 
Translational Activation Assay.
 
3
 
 
 
-UTR of TNF-
 
 
 
 mRNA
(709–1463 from the translation start site) was inserted into XbaI– 
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BamHI site of pGL3-promoter vector (Promega) to construct
pGL3 TNF ARE(
 
 
 
). pGL3 TNF ARE(
 
 
 
), in which a 69-bp
element (from 1128 to 1196) containing six reiterated repeats
of the (T)TAAAT(AT) motif was deleted from pGL3 TNF
ARE(
 
 
 
), was generated by site-directed deletion as described
previously (27). CFTL-15 cells were transfected with either
pGL3 TNF ARE(
 
 
 
) or pGL3 TNF ARE(
 
 
 
) in the presence of
pRL-TK at 960 
 
 
 
F/300 V. Where indicated, pcDNA3 Stat6,
pcDNA3 Stat6VT, or pcDNA3 was cotransfected. After cells
were cultured in complete RPMI 1640 medium at 37
 
 
 
C for 12 h,
aliquoted cells were left treated or untreated with 10 ng/ml IL-4
for another 12 h. Firefly luciferase activity of pGL3 TNF
ARE(
 
 
 
) or pGL3 TNF ARE(
 
 
 
) was normalized by Renilla lu-
ciferase activity of pRL-TK.
 
Analysis of mRNA Decay.
 
pTet-BBB vector, in which tet-
responsive element drives rabbit 
 
 
 
-globin transcription, and pTet-
BBB ARE
 
TNF
 
, in which TNF-
 
 
 
 ARE is inserted to pTet-BBB
vector at downstream of rabbit 
 
 
 
-globin gene, were gifts from
A.B. Shyu (The University of Texas Houston Medical School,
Houston, Texas; reference 28). To measure the rate of mRNA
decay, we modified the experimental system that was developed
by Loflin et al. (28). In brief, CFTL-15 cells were first infected
with MSCV-Stat6VT-IRES-Thy1.1 retrovirus or MSCV-IRES-
Thy1.1 retrovirus (as a control). Infected cells (Thy1.1
 
 
 
 cells)
were purified by magnetic cell sorting and transfected with pTet-
BBB ARE
 
TNF
 
 or pTet-BBB in the presence of pTet-Off vector,
which expresses the tet-responsive transcriptional activator (BD
Biosciences and CLONTECH Laboratories, Inc.). G418-resis-
tant clones were selected by limiting dilution and the presence of
pTet-Off as well as pTet-BBB ARE
 
TNF
 
 or pTet-BBB vector in
the clone was confirmed by PCR. These clones were cultured in
the presence of 100 ng/ml doxycycline (DOX) for 16 h, and
DOX was removed from the culture for 4 h to resume transcrip-
tion from pTet-BBB ARE
 
TNF
 
 or pTet-BBB. These clones were
added with DOX to block further transcription. At indicated
times after the addition of DOX, total RNA was isolated and the
amount of rabbit 
 
 
 
-globin mRNA was determined by Taqman
PCR analysis using ABI PRISM 7000 (Applied Biosystems). The
following primers and a fluorogenic probe were used: sense
primer, 5
 
 
 
-TCGCTGCAAATGCTGTTATGAAC-3
 
 
 
; antisense
primer, 5
 
 
 
-GAATTCTTTGCCAAAATGATGAGA-3
 
 
 
; and
probe, 5
 
 
 
-FAM-CTGGACAACCTCAAG-MGB-3
 
 
 
. The lev-
els of rabbit 
 
 
 
-globin mRNA were normalized to the levels of
glyceraldehyde-3-phosphate dehydrogenase mRNA (Applied
Biosystems).
 
RT-PCR Assay.
 
Total RNA was prepared and RT-PCR
was performed as described previously (29). PCR primers for
TTP cDNA were used as follows: 5
 
 
 
-TCTCTGCCATCTAC-
GAGAGCCTC-3
 
 
 
 and 5
 
 
 
-GCTGATGCTTTGTCGCAGCA-
CATG-3
 
 
 
. RT-PCR for 
 
 
 
-actin was performed as a control. All
PCR amplifications were performed at least three times with
multiple sets of experimental RNAs.
Figure 1. IL-4 inhibits IgE-
induced neutrophil recruit-
ment into the peritoneal cavity
through a Stat6-dependent
mechanism. (A) IgE engagement
induces neutrophil recruitment
into the peritoneal cavity. Anti-
DNP IgE or PBS (as a control)
was first injected intravenously
to BALB/c mice. DNP-HSA or
saline (as a control) was injected
intraperitoneally to the mice 25 h
after anti-DNP IgE sensitization.
8 h after DNP-HSA injection,
the number of total cells, neutro-
phils, and mast cells in the peri-
toneal lavage fluid was deter-
mined. Data are mean   SD
from five mice in each group. *,
Significantly  different from the
mean value of control group
(saline injection). *, P   0.05.
**, P   0.01. (B and C) IL-4
inhibits IgE-induced neutrophil
recruitment through a Stat6-
dependent  mechanism. Similar
to A, anti-DNP IgE or PBS was
injected intravenously to Stat6-
deficient (Stat6 / ) mice or the
littermate wild-type (WT) mice.
1  g recombinant IL-4 or PBS
(as a control) was injected intra-
peritoneally to the mice 24 h
after anti-DNP IgE sensitization.
1 h later, DNP-HSA or saline
was injected intraperitoneally to
the mice. 8 h after DNP-HSA
injection, the number of total
cells, neutrophils, and mast cells (B) as well as the amount of TNF-  (C) in the peritoneal lavage fluid was determined. Data are mean   SD from four
mice in each group. ND, not detectable. *, Significantly different from the mean value of control group (PBS). *, P   0.05. **, P   0.01.Basis of TNF-  Suppression by IL-4 1720
Immunoblotting. Whole cell extracts were prepared and im-
munoblotting was performed as described previously (20). Anti-
serum to TTP (H-120) was purchased from Santa Cruz Biotech-
nology, Inc.
TTP Promoter Assay. Murine TTP promoter, either  691 to
 59 or  524 to  59, was amplified by PCR using a 2.1-kb
fragment of murine TTP promoter (a gift from P.J. Blackshear,
National Institute of Environmental Health Sciences, Research
Triangle Park, NC; reference 30) as a template and inserted into
KpnI–XhoI site of pGL3-basic vector (Promega) to generate
TTP-691Luc or TTP-524Luc. TTP-691mtLuc, in which Stat6
binding site (TTCctaaGAA from  576 to  567) was mutated to
TTTctaaGAA, was generated using a PCR-based site-directed
mutagenesis kit (Stratagene). CFTL-15 cells were infected
with MSCV-Stat6VT-IRES-Thy1.1 retrovirus or MSCV-IRES-
Thy1.1 retrovirus (as a control) and infected cells (Thy1.1  cells)
were purified by magnetic cell sorting. The purified cells were
transfected with either TTP-691Luc, TTP-524Luc, or TTP-
691mtLuc in the presence of pRL-TK at 960  F/300 V. After
cells were cultured in complete RPMI 1640 medium at 37 C for
24 h, firefly luciferase activity of TTP-691Luc, TTP-524Luc, or
TTP-691mtLuc was measured and normalized by Renilla lu-
ciferase activity of pRL-TK.
TTP Short Hairpin RNA (shRNA)–expressing CFTL-15 Cells.
To deplete the expression of TTP, we used RNAi with shRNA
expression vector (pSuppressor Neo; Imgenex). Targets of small
interfering RNA are as follows: TTP shRNA A (5 -ACTCG-
GACTCCATCCCGTCT-3 , corresponding to 160–179 of the
murine TTP mRNA); TTP shRNA B (5 -GCATCAGCT-
TCTCCGGCTTG-3 , corresponding to 586–605); and TTP
shRNA C (5 -GAGACCCTAACCAGGCCTG-3 , correspond-
ing to 763–781). We confirmed that all sequences were unique
for TTP (unpublished data). Construction of shRNA expression
vectors was performed according to the manufacturer’s instruc-
tion. CFTL-15 cells were transfected with these vectors and cul-
tured with 0.8 mg/ml G418 at 37 C for 14 d. G418-resistant
clones were selected by limiting dilution.
Data Analysis. Data are summarized as mean   SD. The sta-
tistical analysis of the results was performed by the unpaired Stu-
dent’s t test. p-values  0.05 were considered significant.
Results
IL-4 Inhibits IgE-induced TNF-  Production and Neutrophil
Recruitment through a Stat6-dependent Mechanism. First, we
investigated the role of IL-4–Stat6 signaling in IgE-medi-
ated inflammatory responses in vivo. We used a murine
model of IgE-dependent late-phase reaction, in which
neutrophil recruitment is induced into the peritoneal cavity
upon IgE engagement through the activation of mast cells
(22). Mice were passively sensitized with anti-DNP IgE,
and subsequently IgE was engaged by an intraperitoneal in-
jection of DNP-HSA. As shown in Fig. 1 A, at 8 h after
DNP-HSA injection, the number of leukocytes in the
peritoneal cavity was increased in the mice that were sensi-
tized with anti-DNP IgE. The number of neutrophils re-
covered from the peritoneal cavity was significantly in-
creased by DNP-HSA injection in sensitized mice (saline
Figure 2. IL-4–Stat6 signaling inhibits TNF- 
production in mast cells. (A) IL-4 inhibits IgE-induced
TNF-  release from WT BMMCs but not from
Stat6 /  BMMCs. WT BMMCs or Stat6 /  BMMCs
were incubated with anti-DNP IgE for 2 h, and sur-
face IgE was cross-linked with or without DNP-HSA
in the presence or absence of 10 ng/ml IL-4. 24 h
later, the amount of TNF-  in the supernatant was
measured by ELISA. Data are mean   SD from five
independent experiments. ND, not detectable. *, Sig-
nificantly different from the mean value of control
group (PBS). *, P   0.01. (B) IL-4 inhibits IgE-induced
TNF-  production from WT BMMCs but not from
Stat6 /  BMMCs. WT BMMCs or Stat6 /  BMMCs
were incubated with anti-DNP IgE and surface IgE
was cross-linked with or without DNP-HSA for 6 h
in the presence or absence of 10 ng/ml IL-4. Intracel-
lular TNF-  was analyzed on FACS®. Representative
FACS® profiles from five independent experiments
are shown. (C) IL-4 inhibits A23187-induced
TNF-  production from WT BMMCs but not from
Stat6 /  BMMCs. WT BMMCs or Stat6 /  BMMCs
were stimulated with or without 500 ng/ml A23187
in the presence or absence of 10 ng/ml IL-4. 24 h
later, the amount of TNF-  in the supernatant was
measured by ELISA. Data are mean   SD from five
independent experiments. ND, not detectable. *, Sig-
nificantly different from the mean value of control
group (PBS). *, P   0.01. (D) Expression of constitu-
tively active Stat6 (Stat6VT) inhibits TNF-  production.
CFTL-15 cells were infected with MSCV-Stat6VT-
IRES-Thy1.1 or MSCV-IRES-Thy1.1 (as a control)
retroviruses and infected cells (Thy1.1  cells) were
sorted by MACS. Sorted cells were stimulated with or without 500 ng/ml A23187 for 24 h and the amount of TNF-  in the supernatant was
measured by ELISA. Data are mean   SD from five independent experiments. ND, not detectable. *, P   0.01.Suzuki et al. 1721
[2.0   0.4] vs. DNP-HSA [10.4   2.4   105]; mean  
SD; n   5; P   0.01) (Fig. 1 A), whereas the number of
mast cells was not affected by DNP-HSA injection (Fig. 1
A). IL-4 significantly inhibited IgE-induced neutrophil re-
cruitment in the peritoneal cavity by 67% in WT mice
without affecting the number of mast cells (n   4; P  
0.01) (Fig. 1 B). By contrast, IL-4 did not inhibit IgE-
induced neutrophil recruitment in Stat6 /  mice (Fig. 1
B). IL-4 also inhibited IgE-induced TNF-  production in
the peritoneal cavity in WT mice but not in Stat6 /  mice
(Fig. 1 C). These results suggest that IL-4–Stat6 signaling
inhibits TNF-  production and neutrophil recruitment
during IgE- and mast cell–dependent late-phase reactions.
IL-4 Inhibits TNF-  Production in Mast Cells by a Stat6-
dependent Mechanism. To determine whether IL-4 down-
regulates TNF-  production in mast cells and whether
Stat6 is involved in this regulation, next we examined the
effect of IL-4 on IgE-induced TNF-  production in WT
or Stat6 /  BMMCs. When IgE receptors on WT BMMCs
were engaged with anti-DNP IgE plus DNP-HSA, a con-
siderable amount of TNF-  was released (Fig. 2 A).
Stat6 /  BMMCs also released a comparable amount of
TNF-  to WT BMMCs upon IgE engagement (Fig. 2 A).
IL-4 significantly inhibited IgE-induced TNF-  release
from WT BMMCs by 57% (PBS [158.5   11.0] vs. IL-4
[68.2    13.7 pg/ml]; n    5; P    0.01) (Fig. 2 A),
whereas IL-4 did not inhibit IgE-induced TNF-  release
from Stat6 /  BMMCs (PBS [192.9   7.96] vs. IL-4
[211.3   10.3 pg/ml]; n   5) (Fig. 2 A). We evaluated
TNF-  production of BMMCs using intracellular stain-
ing, which enabled us to measure de novo TNF-  pro-
duction by adding monensin 2 h after IgE stimulation. As
shown in Fig. 2 B, IL-4 decreased the number of TNF- 
producing cells in IgE-stimulated WT BMMCs (PBS
[69.3%] vs. IL-4 [35.9%]; percentage TNF- –producing
cells; representative data from five independent experi-
ments) but not in IgE-stimulated Stat6 /  BMMCs (PBS
[65.1%] vs. IL-4 [69.2%]; n   5). These results suggest
that IL-4 inhibits de novo TNF-  production in mast
cells by a Stat6-dependent mechanism.
Because it has been demonstrated that IL-4–Stat6 signal-
ing down-regulates IgE receptors on mast cells (15), it is
possible that IL-4–induced down-regulation of TNF- 
production in IgE-stimulated BMMCs results from the
down-regulation of IgE receptors. To exclude this possibil-
ity, WT BMMCs or Stat6 /  BMMCs were stimulated
with calcium ionophore (A23187), which mimics IgE-
mediated activation, in the presence or absence of IL-4,
and the levels of TNF-  in the supernatant were deter-
mined. Again, IL-4 significantly inhibited TNF-  produc-
tion from A23187-stimulated WT BMMCs (PBS [440.6  
34.5] vs. IL-4 [247.8   14.6 pg/ml]; n   5; P   0.01)
(Fig. 2 C) but not from Stat6 /  BMMCs (PBS [427.5  
74.6] vs. IL-4 [449.2   54.5 pg/ml]; n   5) (Fig. 2 C). In-
tracellular TNF-  staining confirmed that IL-4 inhibited
TNF-  production from A23187-stimulated WT BMMCs
but not from A23187-stimulated Stat6 /  BMMCs (un-
published data). IL-4 also inhibited TNF-  production
from LPS-stimulated WT BMMCs but not from LPS-
stimulated Stat6 /  BMMCs (unpublished data).
Next, we examined whether Stat6 activation is sufficient
to down-regulate TNF-  production in mast cells using a
constitutively active form of Stat6 (Stat6VT) (21). As
shown in Fig. 2 D, when Stat6VT was expressed in a mast
cell line (CFTL-15 cells) using retroviruses, Stat6VT signif-
icantly inhibited A23187-induced TNF-  production
(control virus [186.3   26.0] vs. Stat6VT virus [58.6  
2.83 pg/ml]; n   5; P   0.01). These results indicate that
Stat6 activation is sufficient for the down-regulation of
TNF-  production in mast cells.
Figure 3. The transcriptional activation domain of Stat6
is essential for IL-4–induced down-regulation of TNF- 
production. Stat6 /  BMMCs were infected with retro-
viruses of pMX-WT Stat6-IRES-GFP, pMX-673 Stat6-
IRES-GFP, or pMX-IRES-GFP (as a control). Cells were
stimulated with anti-DNP IgE alone or anti-DNP IgE plus
DNP-HSA for 6 h in the presence or absence of 10 ng/ml
IL-4. Intracellular TNF-  was evaluated together with
GFP by FACS®. Representative FACS® profiles from five
independent experiments are shown.Basis of TNF-  Suppression by IL-4 1722
Transcriptional Activation Domain of Stat6 Is Required for
IL-4–induced Down-regulation of TNF-  Production. To
determine whether transcriptional activity of Stat6 is re-
quired for IL-4–induced down-regulation of TNF-  pro-
duction, we examined the effect of IL-4 on Stat6 / 
BMMCs that were reconstituted with WT Stat6 or 673
Stat6 (20), which lacks the transactivation domain. Stat6 / 
BMMCs were infected with retroviruses of pMX-WT
Stat6-IRES-GFP, pMX-673 Stat6-IRES-GFP, or pMX-
IRES-GFP (as a control) and stimulated with IgE engage-
ment (anti-DNP IgE   DNP-HSA) in the presence or ab-
sence of IL-4. Consistent with the data depicted in Fig. 2
(A and B), IL-4 inhibited IgE-induced TNF-  production
in WT Stat6-expressing Stat6 /  BMMCs (61.8 vs. 14.7%;
percentage TNF- –producing cells in infected GFP  pop-
ulations) (Fig. 3, f vs. h). By contrast, IL-4 did not inhibit
IgE-induced TNF-  production in 673 Stat6-expressing
Stat6 /  BMMCs (64.9 vs. 62.5%) (Fig. 3, j vs. l) or in
control Stat6 /  BMMCs (64.0 vs. 63.5%) (Fig. 3, b vs. d).
In noninfected populations (GFP  cells), IL-4 did not in-
hibit IgE-induced TNF-  productions even when WT
Stat6-expressing cells coexisted in the culture (Fig. 3, f vs.
h). These results indicate that the transcriptional activity of
Stat6 is required for IL-4–induced down-regulation of
TNF-  production.
IL-4 Does Not Inhibit Transcription from TNF-  Promoter.
To further address molecular mechanisms of IL-4–induced
down-regulation of TNF-  production in mast cells, we
next examined the effect of IL-4 on TNF-  promoter ac-
tivity. In this experiment, pGL3TNF (25) that contains
full-length murine TNF-  promoter (26) was used as a re-
porter construct. CFTL-15 cells were transfected with
pGL3TNF and the effect of IL-4 on A23187-induced tran-
scription of pGL3TNF was examined. On the contrary to
our expectation, IL-4 did not inhibit A23187-induced tran-
scription of pGL3TNF (Fig. 4). IL-4 did not inhibit the
transcription of pGL3TNF, even when WT Stat6 was co-
expressed in CFTL-15 cells (Fig. 4). In addition, the ex-
pression of Stat6VT did not inhibit A23187-induced tran-
scription of pGL3TNF (Fig. 4), although Stat6VT did
inhibit A23187-induced TNF-  production in CFTL-15
cells (Fig. 2 D). These results suggest that IL-4–Stat6 signal-
ing does not inhibit TNF-  promoter activity.
IL-4–Stat6 Signaling Down-regulates TNF-  mRNA Sta-
bility by an ARE-dependent Mechanism. The amount of
mRNA is controlled not only by the de novo transcription
but also by the stability of mRNA (18, 31). Given that the
AREs residing in the 3 UTR of TNF-  mRNA has been
shown to be important for the regulation of gene expres-
sion (27, 32, 33), next we examined whether the ARE is
involved in IL-4–induced down-regulation of TNF-  pro-
duction in mast cells. We prepared two reporter constructs:
pGL3 TNF ARE( ), in which 3 UTR of TNF-  mRNA
was inserted just after the luciferase gene of pGL3-pro-
moter vector and pGL3 TNF ARE( ), in which 69 bp of
ARE was deleted from pGL3 TNF ARE( ) (Fig. 5 A).
CFTL-15 cells were transfected with pGL3 TNF ARE( )
or pGL3 TNF ARE( ) in the presence of pcDNA3 Stat6,
pcDNA3 Stat6VT, or pcDNA3 (as a control) and stimu-
lated with or without IL-4. As shown in Fig. 5 B, IL-4 in-
hibited the luciferase activity of pGL3 TNF ARE( ). IL-
4–induced down-regulation of pGL3 TNF ARE( ) was
more profound when WT Stat6 was coexpressed in CFTL-
15 cells (Fig. 5 B). The expression of Stat6VT also inhib-
ited the activity of pGL3 TNF ARE( ) even in the
absence of IL-4 stimulation (Fig. 5 B). In contrast, IL-4
stimulation or the expression of Stat6VT did not inhibit the
activity of pGL3 TNF ARE( ) (Fig. 5 B). These results
suggest that ARE residing in the 3 UTR of TNF- 
mRNA is involved in IL-4–induced down-regulation of
TNF-  production in mast cells.
Because it has been demonstrated that the ARE in the
3 UTR of TNF-  mRNA controls both mRNA stability
Figure 4. IL-4–Stat6 signaling
does not inhibit TNF-  pro-
moter activity. CFTL-15 cells
were transfected with pGL3TNF
and pRL-TK in the presence of
pcDNA3 Stat6, pcDNA3
Stat6VT, or pcDNA3 (as a con-
trol). 12 h later, cells were stimu-
lated with or without 500 ng/ml
A23187 in the presence or absence
of 10 ng/ml IL-4. The luciferase
activity was measured by the
dual luciferase reporter system
another 12 h later. Data are
mean   SD from five indepen-
dent experiments.
Figure 5. ARE in 3 UTR of TNF-  mRNA is essential for IL-4–
induced down-regulation of TNF-  production. (A) Schema of reporter
constructs of pGL3 TNF ARE( ) and pGL3 TNF ARE( ). (B) IL-4
inhibits the luciferase activity of pGL3 TNF ARE( ) but not of pGL3
TNF ARE( ) by a Stat6-dependent mechanism. CFTL-15 cells were
transfected with pRL-TK and either pGL3 TNF ARE( ) or pGL3 TNF
ARE( ) in the presence of pcDNA3 Stat6, pcDNA3 Stat6VT, or
pcDNA3 (as a control). 12 h later, cells were stimulated with or without
10 ng/ml IL-4. The luciferase activity was measured by the dual luciferase
reporter system another 12 h later. Data are mean   SD from five inde-
pendent experiments. *, P   0.05. **, P   0.01.Suzuki et al. 1723
and translation (27), next we examined the effect of Stat6
activation on the regulation of ARE-dependent mRNA
stability using a more direct system established by Loflin et
al. (28). CFTL-15 cells that were infected with Stat6VT
retrovirus or control retrovirus were transfected with pTet-
BBB ARETNF or pTet-BBB (Fig. 6 A) in the presence of
pTet-Off vector. pTet-BBB ARETNF– or pTet-BBB–
expressing cells were cultured in the absence of DOX for
4 h to resume transcription of rabbit  -globin from
pTet-BBB ARETNF or pTet-BBB. After further transcrip-
tion was blocked by adding DOX, the amount of rabbit
 -globin mRNA was examined by Taqman PCR analysis
(Fig. 6 B). Even in the absence of Stat6VT expression, the
decay of rabbit  -globin mRNA was more rapid in pTet-
BBB ARETNF-expressing cells than that in pTet-BBB–
expressing cells (Fig. 6 B). Furthermore, the decay of rabbit
 -globin mRNA was significantly enhanced by the expres-
sion of Stat6VT in pTet-BBB ARETNF-expressing cells
(Fig. 6 B). On the other hand, the expression of Stat6VT
did not affect the decay of rabbit  -globin mRNA in pTet-
BBB–expressing cells (Fig. 6 B). These results indicate that
Stat6 activation induces TNF-  mRNA destabilization in
an ARE-dependent manner.
Stat6 Activation Induces the Expression of TTP in Mast
Cells. Recently, it has been shown that TTP, the proto-
type member of a zinc-finger family of RNA binding pro-
teins (16–18), regulates the expression of certain cytokines
including TNF-  by destabilizing the mRNA in an ARE-
dependent manner (16, 27, 33). To determine whether
TTP is involved in IL-4–induced down-regulation of
TNF-  production, we first examined whether IL-4 in-
duced the expression of TTP in mast cells. Interestingly,
the expression of TTP mRNA was induced in WT
BMMCs within 1 h after IL-4 stimulation (Fig. 7 A). How-
ever, the induction of TTP mRNA was absent in IL-4–
stimulated Stat6 /  BMMCs (Fig. 7 B), indicating that
IL-4–induced TTP expression requires the presence of
Stat6. Enforced expression of Stat6VT also induced TTP
mRNA even in the absence of IL-4 stimulation (Fig. 7 C).
IL-4–induced TTP expression was also detected at protein lev-
els in WT BMMCs but not in Stat6 /  BMMCs (Fig. 7 D).
We further examined whether Stat6-mediated TTP ex-
pression resulted from the direct activation of TTP pro-
moter by Stat6. As shown in Fig. 7 E, TTP-691Luc, a re-
porter construct in which murine TTP promoter ( 691
to  59) drives the luciferase gene, was significantly acti-
vated in CFTL-15 cells that expressed Stat6VT but not in
control CFTL-15 cells (P   0.01). In contrast, when the
Stat6-binding site was mutated (TTP-691mtLuc), the ex-
pression of Stat6VT did not activate the reporter construct
(Fig. 7 E). In addition, the expression of Stat6VT did not
Figure 6. ARE in 3 UTR of TNF-  mRNA induces rapid decay of
mRNA in Stat6VT expressing cells. (A) Schema of pTet-BBB ARETNF
and pTet-BBB (28). (B) CFTL-15 cells were infected with MSCV-
Stat6VT-IRES-Thy1.1 retrovirus or control MSCV-IRES-Thy1.1 retro-
virus. Sorted Thy1.1  cells were transfected with either pTet-BBB
ARETNF or pTet-BBB in the presence of pTet-Off and G418-resistant
clones were selected by limiting dilution. These clones were cultured in
the absence of DOX for 4 h to resume transcription from pTet-BBB
ARETNF or pTet-BBB, which was followed by the addition of 100 ng/ml
DOX to block further transcription. At indicated times after the addition
of DOX, total RNA was isolated and Taqman PCR analysis for rabbit
 -globin and glyceraldehydes-3-phosphate dehydrogenase (as a control)
was performed. Representative data from five independent experiments
are shown.
Figure 7. IL-4 induces the
expression of tristetraprolin (TTP)
by a Stat6-dependent mechanism.
(A) IL-4 induces the expression
of TTP mRNA in BMMCs.
WT BMMCs were stimulated
with 10 ng/ml IL-4 at 37 C. At
indicated times after IL-4 stimu-
lation, total RNA was prepared
and RT-PCR for TTP and
 -actin (as a control) was per-
formed. Representative data from
five independent experiments are
shown. (B) IL-4–induced TTP
mRNA expression requires
Stat6. WT BMMCs or Stat6 / 
BMMCs were stimulated with
10 ng/ml IL-4 for 60 min and
RT-PCR for TTP and  -actin
was performed. Representative
data from five independent ex-
periments are shown. (C) Stat6
activation is sufficient for the
induction of TTP mRNA ex-
pression. CFTL-15 cells were
infected with pMX-Stat6VT-
IRES-Thy1.1 retrovirus or pMX-IRES-Thy1.1 retrovirus (as a control).
Total RNA was prepared from sorted Thy1.1  cells and subjected to
RT-PCR analysis for TTP. Representative data from five independent
experiments are shown. (D) IL-4 induces TTP expression at protein
levels in WT BMMCs but not in Stat6 /  BMMCs. WT BMMCs and
Stat6 /  BMMCs were stimulated with 10 ng/ml IL-4 for 4 h, and
whole cell extracts were subjected to Western blotting with anti-TTP
antibody. Representative data from four independent experiment are
shown. (E) Stat6 directly activates TTP promoter in mast cells. CFTL-15
cells were infected with MSCV-Stat6VT-IRES-Thy1.1 retrovirus or
MSCV-IRES-Thy1.1 retrovirus (as a control). Infected cells (Thy1.1 
cells) were purified and transfected with either TTP-691Luc, TTP-
524Luc, or TTP-691mtLuc in the presence of pRL-TK. 24 h later, firefly
luciferase activity of TTP-691Luc, TTP-524Luc, or TTP-691mtLuc was
measured and normalized by Renilla luciferase activity of pRL-TK. Data
are mean   SD of four independent experiments. *, P   0.01.Basis of TNF-  Suppression by IL-4 1724
activate TTP-524Luc, a construct in which the Stat6-
binding site was deleted (Fig. 7 E), although TTP-524Luc
exhibited an equivalent baseline activity to TTP-691Luc
(Fig. 7 E). These results suggest that the activated Stat6 di-
rectly induces the transcription from TTP promoter in
mast cells.
TTP Is Required for IL-4–induced Down-regulation of TNF- 
Production in Mast Cells. Finally, we examined the ef-
fect of TTP depletion on IL-4–induced down-regulation
of TNF-  production in mast cells. We prepared several
shRNA RNAi constructs and tested the efficiency of the
depletion. As shown in Fig. 8 A, TTP shRNA A signifi-
cantly inhibited the expression of TTP mRNA in IL-4–
stimulated CFTL-15 cells. In contrast, TTP shRNA B or
TTP shRNA C did not inhibit the expression of TTP
mRNA at all (Fig. 8 A). We selected several clones that sta-
bly expressed TTP shRNA A and found that IL-4–induced
TTP expression was severely decreased in A1 and A2 cells
(Fig. 8 B). In contrast, Ctrl 1 cells that were stably trans-
fected with a control construct (pSuppressor Neo) ex-
pressed a significant amount of TTP mRNA upon IL-4
stimulation (Fig. 8 B). We compared the effect of IL-4 on
A23187-induced TNF-  production in these clones. Inter-
estingly, A1 and A2 cells, but not Ctrl1 cells, were resistant
to IL-4–induced down-regulation of TNF-  production
(Fig. 8 C). These results suggest that TTP is required for
IL-4–induced down-regulation of TNF-  production
from activated mast cells.
Discussion
In this paper, we show that IL-4 inhibits TNF-  produc-
tion from activated mast cells through a Stat6-dependent
TTP expression. First, we found that IL-4 inhibited TNF- 
production in mast cells in vitro as well as in vivo by a
Stat6-dependent mechanism (Figs. 1–3). Second, we found
that IL-4–Stat6 signaling down-regulated TNF-  mRNA
stability in an ARE-dependent manner (Figs. 5 and 6).
Third, we found that IL-4 induced the expression of TTP,
which promotes ARE-dependent mRNA destabilization
(16–18), in mast cells by a Stat6-dependent mechanism (Fig.
7). Finally, depletion of TTP expression by RNAi blocked
IL-4–induced down-regulation of TNF-  production in
mast cells (Fig. 8). These results indicate that Stat6-induced
TTP expression and subsequent ARE-dependent mRNA
destabilization are responsible for IL-4–induced down-reg-
ulation of TNF-  production in mast cells.
We show that IL-4–Stat6 signaling inhibits TNF-  pro-
duction from mast cells that are stimulated not only with
IgE engagement (Figs. 1–3) but also with LPS stimulation
(not depicted). The antiinflammatory properties of IL-4 are
well recognized as important negative regulators of proin-
flammatory gene expression, especially in monocytes and
macrophages (34). Thus, our results indicate that mast cells
are also targets of IL-4 to function as an antiinflammatory
cytokine. Our findings are consistent with a previous find-
ing by Matsukawa et al. (35) that TNF-  production in the
peritoneal cavity in experimental peritonitis, in which mast
cell–derived TNF-  plays a critical role in the protection
of bacterial infection (5, 6), is enhanced in Stat6 /  mice.
We have found that transcriptional activity of Stat6 is re-
quired for IL-4–induced down-regulation of TNF-  pro-
duction in mast cells (Fig. 3). In addition, we have found
that the expression of D685A Stat6, which exhibits a stron-
ger transcriptional activity than WT Stat6 in mast cells (20),
enhances IL-4–induced down-regulation of TNF-  pro-
duction in mast cells (unpublished data). We have also
found that the expression of a constitutively active Stat6VT
down-regulates TNF-  production in mast cells (Fig. 2).
Although, in addition to Stat6, IL-4R mediates its re-
sponses through activation of other pathways, including in-
sulin receptor substrate 1/2 (12), our results indicate that
Stat6 is essential for IL-4–induced down-regulation of
TNF-  production.
Figure 8. IL-4 does not inhibit TNF-  production in TTP-depleted
cells. (A) TTP shRNA A inhibits IL-4–induced TTP expression. CFTL-15
cells were transfected with TTP short hairpin RNA (shRNA) vectors
(TTP shRNA A, B, and C) or pSuppressor Neo (as a control) and cultured
in the presence of IL-3 and G418 (0.8 mg/ml) for 14 d. G418-resistant
cells were stimulated with or without IL-4 for 60 min, and the amount of
TTP mRNA was evaluated by RT-PCR. Representative data from five
independent experiments are shown. (B) IL-4–induced TTP expression is
diminished in A1 and A2 cells. CFTL-15 cells were transfected with TTP
shRNA A, and G418-resistant clones (A1 and A2) were selected by limiting
dilution. As a control, CFTL-15 cells were transfected with pSuppressor
Neo and G418-resistant clone (Ctrl 1) was selected by limiting dilution.
These cells were stimulated with or without 10 ng/ml IL-4 for 60 min
and the amount of TTP mRNA was evaluated by RT-PCR. Representative
data from three independent experiments are shown. (C) IL-4 does not
inhibit A23187-induced TNF-  production in A1 and A2 cells. A1 cells,
A2 cells, and Ctrl1 cells were stimulated with or without 500 ng/ml A23187
for 24 h in the presence or absence of 10 ng/ml IL-4. The amounts of
TNF-  in the supernatant were measured by ELISA. Data are mean  
SD from five independent experiments. ND, not detectable. *, P   0.01.Suzuki et al. 1725
We demonstrate that IL-4–induced down-regulation of
TNF-  production results from the ARE-dependent
mRNA destabilization (Figs. 5 and 6), but not from the in-
hibition of TNF-  promoter activity (Fig. 4). Increasing
evidence has shown that the presence of ARE in the 3 -
UTR of transcripts is associated with the regulation of
mRNA stability (16–18). Indeed, in the case of TNF- ,
the importance of ARE-dependent mRNA destabilization
has been demonstrated in vitro as well as in vivo (27, 33),
although transcription (36), splicing (37), and protein pro-
cessing (38) are also involved in TNF-  production. Be-
cause ARE is found in a number of genes (17, 18), it is
plausible that IL-4 may inhibit the expression of some
other genes through the destabilization of mRNA. This
possibility is under investigation in our laboratory.
We show that IL-4–Stat6 signaling induces the expres-
sion of TTP in mast cells through Stat6-mediated activa-
tion of TTP promoter (Fig. 7). Therefore, together with
the findings of IL-4–induced TTP-dependent down-regu-
lation of TNF-  production in mast cells (Fig. 8), our re-
sults indicate that Stat6-induced TTP expression mediates
ARE-dependent destabilization of TNF-  mRNA in mast
cells. The importance of TTP in the regulation of TNF- 
production has been clearly demonstrated using TTP-defi-
cient (TTP / ) mice (33, 39, 40). The phenotype of
TTP /  mice, including cachexia, dermatitis, conjunctivi-
tis, and destructive arthritis, can be largely prevented by the
neutralization of TNF-  (39), implicating an excess of cir-
culating TNF-  in the pathogenesis of TTP /  mice. In
addition, it has been demonstrated that macrophages de-
rived from TTP /  mice produce more TNF-  mRNA
than macrophages from WT mice (40). Moreover, TNF- 
mRNA has been shown to be markedly stabilized in
TTP /  cells (33), implicating TTP as an important stimu-
lator of decay of TNF-  mRNA. It has also been shown
recently that TTP recruits the exosome to ARE-contain-
ing mRNA and thereby promotes the rapid decay of the
mRNA (41). Thus, our findings that IL-4–Stat6 signaling
induces the expression of TTP provide a novel insight into
the ARE-dependent gene regulation in IL-4–rich environ-
ments such as allergic diseases or parasitic infection.
As aforementioned, our results indicate that IL-4 pre-
vents TNF-  production from mast cells through Stat6-
induced TTP expression (Figs. 7 and 8). IL-10, another an-
tiinflammatory cytokine, also inhibits the production of
TNF-  through an ARE-dependent mechanism (42).
However, interestingly, the molecular basis for the IL-10–
induced inhibition is different from that of IL-4. It has been
shown that IL-10–induced down-regulation of TNF- 
production does not require the presence of TTP and does
not alter mRNA stability (42). Instead, IL-10–induced
down-regulation of TNF-  production is exerted through
the inhibition of p38 mitogen-activated protein (MAP) ki-
nase–mediated translation of TNF-  (42). It has also been
demonstrated that p38 MAP kinase phosphorylates TTP
protein (43, 44), and that the phosphorylated TTP loses its
activity (44). Because it has been shown that IL-10 inhibits
p38 MAP kinase (42), IL-10 may also inhibit TNF-  pro-
duction by inhibiting p38 MAP kinase–mediated inactiva-
tion of TTP.
In conclusion, we have shown that IL-4–Stat6 signal-
ing induces the expression of TTP in mast cells and,
thus, down-regulates TNF-  production by destabilizing
mRNA in an ARE-dependent manner. Because an excess
of TNF-  is involved in many inflammatory diseases, in-
cluding rheumatoid arthritis (45) and idiopathic inflamma-
tory bowel diseases (46), the modulation of IL-4–Stat6 sig-
naling may be useful as a therapeutic tool for rheumatoid
arthritis or inflammatory bowel disease through the inhibi-
tion of TNF-  production.
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